Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-dummy, Observer-Blind, Study to Evaluate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Compared to Pfizer-BioNTech COVID-19 Vaccine in Healthy Seronegative Adults Aged 18 to 64 Years

NCT05175742 is registered in ClinicalTrials.gov with Providence Therapeutics Holdings Inc. as lead sponsor.

NCT NCT05175742
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05175742 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-dummy, Observer-Blind, Study to Evaluate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Compared to Pfizer-BioNTech COVID-19 Vaccine in Healthy Seronegative Adults Aged 18 to 64 Years
Lead sponsor
Providence Therapeutics Holdings Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 17, 2021
Completion date
March 29, 2023
Enrollment
565 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

covid19 vaccine